Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2378666 | 0.90 | CTSK (0.31) | — | |
| SCHEMBL2379450 | 0.90 | CTSK (0.31) | — | |
| SCHEMBL17500736 | 0.84 | — | — | |
| SCHEMBL2377044 | 0.82 | DPP4 (0.32) | ALDH1A1 | |
| SCHEMBL2394609 | 0.82 | DPP4 (0.32) | ALDH1A1 | |
| SCHEMBL27997009 | 0.82 | CTSK (0.35) | KDM4EALDH1A1 | |
| SCHEMBL3758975 | 0.82 | — | — | |
| SCHEMBL20485409 | 0.79 | — | — | |
| SCHEMBL6475659 | 0.78 | HSD11B1 (0.34) | ALDH1A1 | |
| SCHEMBL6475939 | 0.77 | HSD11B1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116057061-A | USP7 inhibitors | 首药控股(北京)股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115215883-A | USP7 inhibitors | 首药控股(北京)股份有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-114907368-A | USP7 inhibitors | 首药控股(北京)股份有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-114656479-A | USP7 inhibitor | 首药控股(北京)股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-114539283-A | USP7 inhibitor | 首药控股(北京)股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2022048498-A1 | USP7 INHIBITOR | 首药控股(北京)股份有限公司 | 2022-03-10 | — | — | WO | disclosed |
| CN-107207435-B | Process for preparing 4-cyanopiperidine hydrochloride | 拜耳作物科学股份公司 | 2020-05-19 | — | — | CN | disclosed |
| EP-3245190-B1 | METHOD FOR PREPARING 4-CYANOPIPERIDINE HYDROCHLORIDE | BAYER CROPSCIENCE AG (DE) | 2018-12-26 | — | — | EP | disclosed |
| US-10150731-B2 | Method for preparing 4-cyanopiperidine hydrochloride | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-12-11 | — | — | US | disclosed |
| US-20170369442-A1 | METHOD FOR PREPARING 4-CYANOPIPERIDINE HYDROCHLORIDE | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-12-28 | — | — | US | disclosed |
| EP-3245190-A1 | METHOD FOR PREPARING 4-CYANOPIPERIDINE HYDROCHLORIDE | Bayer CropScience Aktiengesellschaft (DE) | 2017-11-22 | — | — | EP | disclosed |
| WO-2016113277-A1 | METHOD FOR PREPARING 4-CYANOPIPERIDINE HYDROCHLORIDE | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-07-21 | — | — | WO | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-7888374-B2 | Inhibitors of c-jun N-terminal kinases | ABBOTT LABORATORIES (US) | 2011-02-15 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| CN-101228127-A | Novel Piperidine Derivatives | BANYU PHARMA CO LTD (JP) | 2008-07-23 | — | — | CN | disclosed |
| EP-1939189-A1 | DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
| WO-2006083673-A2 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF C-JUN N-TERMINAL KINASES | ABBOTT LABORATORIES (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | MAPKAPK3, MAP3K3, MAPK3 | F2R 2994/4885SCN9A 4026/4885KDM4E 2987/4885 |
| US-20170369442-A1 | METHOD FOR PREPARING 4-CYANOPIPERIDINE HYDROCHLORIDE | QDPR, DCPS, CIAPIN1 | F2R 4348/4885SCN9A 980/4885KDM4E 298/4885 |
| US-10150731-B2 | Method for preparing 4-cyanopiperidine hydrochloride | QDPR, DCPS, CIAPIN1 | F2R 4348/4885SCN9A 980/4885KDM4E 298/4885 |
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | F2R 1815/4885SCN9A 705/4885KDM4E 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.